Lantheus announces corporate plans, CAD agent strategy

03/24/2013 | AuntMinnie.com (free registration)

Lantheus Medical Imaging said it is undertaking measures to cut costs, including decreasing internal research and development and obtaining a partner for the final development of its PET radiopharmaceutical for diagnosing coronary artery disease, 18F-flurpiridaz. The partner will help with the remainder of Phase III development and commercialization, Lantheus said.

View Full Article in:

AuntMinnie.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park